Format

Send to

Choose Destination
Clin Cancer Res. 2019 Feb 15;25(4):1331-1342. doi: 10.1158/1078-0432.CCR-18-1846. Epub 2018 Nov 12.

Whole-body Imaging of Cell Death Provides a Systemic, Minimally Invasive, Dynamic, and Near-real Time Indicator for Chemotherapeutic Drug Toxicity.

Author information

1
Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
2
Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
3
Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois.
4
Center for Advanced Molecular Imaging, Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois.
5
Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
6
Department of Chemistry, Northwestern University, Evanston, Illinois.
7
Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois. m-zhao@northwestern.edu mazar@monopartx.com.
8
Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
9
Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. m-zhao@northwestern.edu mazar@monopartx.com.

Abstract

PURPOSE:

Response to toxicity in chemotherapies varies considerably from tissue to tissue and from patient to patient. An ability to monitor the tissue damage done by chemotherapy may have a profound impact on treatment and prognosis allowing for a proactive management in understanding and mitigating such events. For the first time, we investigated the feasibility of using whole-body imaging to map chemotherapeutic drug-induced toxicity on an individual basis.

EXPERIMENTAL DESIGN:

In a preclinical proof-of-concept, rats were treated with a single clinical dose of cyclophosphamide, methotrexate, or cisplatin. In vivo whole-body imaging data were acquired using 99mTc-duramycin, which identifies dead and dying cells as an unambiguous marker for tissue injury in susceptible organs. Imaging results were cross-validated using quantitative ex vivo measurements and histopathology and compared with standard blood and serum panels for toxicology.

RESULTS:

The in vivo whole-body imaging data detected widespread changes, where spatially heterogeneous toxic effects were identified across different tissues, within substructures of organs, as well as among different individuals. The signal changes were consistent with established toxicity profiles of these chemotherapeutic drugs. Apart from generating a map of susceptible tissues, this in vivo imaging approach was more sensitive compared with conventional blood and serum markers used in toxicology. Also, repeated imaging during the acute period after drug treatment captured different kinetics of tissue injury among susceptible organs in males and females.

CONCLUSIONS:

This novel and highly translational imaging approach shows promise in optimizing therapeutic decisions by detecting and managing drug toxicity on a personalized basis.Toxicity to normal tissues is a significant limitation in chemotherapies. This work demonstrated an in vivo imaging-based approach for characterizing toxicity-induced tissue injury in a systemic, dynamic, and near-real time fashion. This novel approach shows promise in optimizing therapeutic decisions by monitoring drug toxicity on a personalized basis.

PMID:
30420445
PMCID:
PMC6377818
[Available on 2020-02-15]
DOI:
10.1158/1078-0432.CCR-18-1846

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center